LH — Labcorp Holdings Share Price
Last trade - 00:00- $18.17bn
- $23.07bn
- $13.01bn
- 93
- 47
- 97
- 93
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.15 | ||
| PEG Ratio (f) | 0.42 | ||
| EPS Growth (f) | 46.32% | ||
| Dividend Yield (f) | 1.34% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.26 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 16.58 | ||
| Price to Sales | 1.4 | ||
| EV to EBITDA | 13.28 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.22% | ||
| Return on Equity | 9.37% | ||
| Operating Margin | 8.35% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13,978.5 | 13,136.1 | 11,863.9 | 12,161.6 | 13,008.9 | 13,920.98 | 14,577.04 | 2.4% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +103.26 | +16.69 | -39.51 | -46.36 | +25.59 | +73.36 | +9.69 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Directors
- Adam Schechter PRE (56)
- Glenn Eisenberg CFO (60)
- Judith Seltz CHO (58)
- Lance Berberian EVP (58)
- Amy Summy EVP (55)
- Sandra Van Der Vaart EVP (61)
- Brian Caveney EVP (47)
- Paul Kirchgraber EVP (59)
- Mark Schroeder EVP (60)
- Peter Wilkinson SVP (50)
- Peter Neupert LED (65)
- Kerrii Anderson IND (64)
- Jean-Luc Belingard IND (72)
- Jeffrey Davis IND (57)
- D. Gary Gilliland IND (66)
- Garheng Kong IND (45)
- Richelle Parham IND (53)
- Kathryn Wengel IND (55)
- Robert Williams IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 16th, 2024
- Public Since
- April 24th, 1991
- No. of Shareholders
- 1,038
- No. of Employees
- 70,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 83,668,573
- Address
- 358 S Main St, BURLINGTON, 27215
- Web
- https://www.labcorp.com/
- Phone
- +1 3362291127
- Contact
- Christin O'donnell
- Auditors
- Deloitte & Touche LLP
Latest News for LH
Upcoming Events for LH
Q1 2025 Labcorp Holdings Inc Earnings Release
Q1 2025 Labcorp Holdings Inc Earnings Call
Labcorp Holdings Inc Annual Shareholders Meeting
Dividend For L1CA34.SA - 0.7449 BRL
Dividend For LH.N - 0.7200 USD
Q2 2025 Labcorp Holdings Inc Earnings Release
Similar to LH
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ardent Health Partners
New York Stock Exchange
Auna SA
New York Stock Exchange
FAQ
As of Today at 21:41 UTC, shares in Labcorp Holdings are trading at $217.12. This share price information is delayed by 15 minutes.
Shares in Labcorp Holdings last closed at $217.12 and the price had moved by +8.58% over the past 365 days. In terms of relative price strength the Labcorp Holdings share price has outperformed the S&P500 Index by +2.09% over the past year.
The overall consensus recommendation for Labcorp Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Labcorp Holdings dividend yield is 1.33% based on the trailing twelve month period.
Last year, Labcorp Holdings paid a total dividend of $2.88, and it currently has a trailing dividend yield of 1.33%.Looking ahead, shares in Labcorp Holdings are due to go ex-dividend on 2025-05-29 and the next dividend pay date is 2025-06-11.
Labcorp Holdings are due to go ex-dividend on 2025-05-29 and the next dividend pay date is 2025-06-11. The historic dividend yield on Labcorp Holdings shares is currently 1.33%.
To buy shares in Labcorp Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $217.12, shares in Labcorp Holdings had a market capitalisation of $18.17bn.
Here are the trading details for Labcorp Holdings:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: LH
Based on an overall assessment of its quality, value and momentum Labcorp Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Labcorp Holdings is $270.48. That is 24.58% above the last closing price of $217.12.
Analysts covering Labcorp Holdings currently have a consensus Earnings Per Share (EPS) forecast of $16.04 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Labcorp Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +11.51%.
As of the last closing price of $217.12, shares in Labcorp Holdings were trading -5.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Labcorp Holdings PE ratio based on its reported earnings over the past 12 months is 13.15. The shares last closed at $217.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Labcorp Holdings' management team is headed by:
- Adam Schechter - PRE
- Glenn Eisenberg - CFO
- Judith Seltz - CHO
- Lance Berberian - EVP
- Amy Summy - EVP
- Sandra Van Der Vaart - EVP
- Brian Caveney - EVP
- Paul Kirchgraber - EVP
- Mark Schroeder - EVP
- Peter Wilkinson - SVP
- Peter Neupert - LED
- Kerrii Anderson - IND
- Jean-Luc Belingard - IND
- Jeffrey Davis - IND
- D. Gary Gilliland - IND
- Garheng Kong - IND
- Richelle Parham - IND
- Kathryn Wengel - IND
- Robert Williams - IND